

TRANSITIONS

A NEWSLETTER EXCLUSIVELY FOR EQUITY HOLDERS OF TISSUE REGENERATION TECHNOLOGIES

studies underway!

Last quarter we reported that TRT had received conditional approval to conduct an FDA clinical trial with our DermaGold™ device. We are pleased to announce that those conditions have been met and we are currently enrolling patients for the DermaGold clinical trial!

We expect this to be a 10-site study with the first 3 sites, Georgetown University Hospital (Washington, DC), Calvary Hospital (Bronx, NY) and Hastings Indian Medical Center (Tahlequah, OK) ready to treat patients in April. Within 90 days we expect to have the remaining 7 sites online, and within 4 months from the first patient treatment we expect to be treating at all sites. The study will include 200 patients: 100 in the control group and 100 in the treated group. Our goal is to treat and complete follow-up on all 200 patients within 12 months.

We have also received approval to conduct an FDA clinical trial with our LithoGold™ urology device. We are awaiting IRB approval and expect to be treating patients by April. The requirements of this study are to treat 20 patients and provide one week of follow-up data. We hope to have FDA approval to sell LithoGold devices by mid-year 2006.

by any other name

We're changing our name! Soon "Shockwave Technical Service, LLC" will become "Tissue Regeneration Technologies, LLC." The necessary applications have been filed and we hope to receive notice of the legal name change within the next 90 days.

As for your Membership Unit Certificates, never fear! Although they were issued under "Shockwave Technical Service, LLC", formal notice of the name change will be sent to all investors upon completion of the process. This notice shall serve as an addendum to your Membership Unit Certificate(s).

capital count

To date, TRT has raised over \$5.7 million in capital and increased the number of equity holders to almost 200. The Board of Managers has agreed to extend the current offering on a month-to-month basis for the time being to allow latecomers the opportunity to invest.

Univ. of Kentucky

Our first three studies have been completed at the University of Kentucky (UKY). Studies on the skin-flap model, bacteria and periodontal disease were conducted with our DermaGold™ device. We are excited by preliminary findings, and papers are being prepared for publication.

Dr. John Novak, Associate Director of the Center for Oral Health Services at UKY is a member of TRT's Scientific Advisory Board. Working closely with Dr. William Balke, a cardiologist and Senior Associate Dean for Research at the UKY Medical School, Dr. Novak was instrumental in establishing the DermaGold studies at UKY.

UKY has also appointed TRT to the UK Fellows Society and TRT is recognized as a Henry Stites Barker Fellow. This honor was bestowed on TRT in recognition of its contributions in advancing UKY's research efforts through our studies.

veterans affairs

TRT's plan for treating wounded military service members using our Multiwave™ technology is progressing very well. We are working with Dr. Alex Stojadinovik, Assistant Chief of Surgery at Walter Reed Army Medical Center in Washington, DC, to write the treatment protocol. The H.M. Jackson Foundation is also helping to facilitate the project and we hope to be treating veterans within 90 days. This venture could later be expanded to include the Brooke Army Medical Center in San Antonio and Hadassah University Medical Center in Jerusalem.





around the globe

Europe

- Basic research studies are underway in Germany to study the effects of ESWT and Multiwave™ technology on osteitis, cartilage cell growth, and Nitric Oxide (NO) production.
- The Trauma Centre Berlin, the largest burn center in Europe, is conducting a burn study using TRT technology.
- We are conducting a study on the effect of unfocused acoustic waves on plantar fasciitis, and results for the first 35 patients are promising.

Taiwan

Dr. Ching-Jen Wang, one of Taiwan's leading orthopedic surgeons, will soon initiate a study for the treatment of diabetic foot ulcers utilizing TRT technology. The study will take place at Chang Gung Memorial Hospital at Kaohsiung.

China

We have begun the process of obtaining regulatory approval to commence a study for the treatment of Avascular Necrosis of the femoral head (AVN) with the DermaGold. AVN, the same disease that ended Bo Jackson's professional football and baseball careers, represents 1 million new cases per year in China, a huge potential market.

Worldwide Distribution

Currently MTS/TRT has 13 distributors worldwide representing our products in 16 countries throughout North America, Europe, Asia and Africa. We soon expect to have a distributor for South America as well.

across the nation

LithoGold™ Debut!

TRT recently attended the annual meeting of the Urology Society of America, the largest lithotripsy conference in the nation. The 3-day meeting in San Francisco was our first opportunity to showcase the LithoGold in the U.S., and the response was tremendous! Because it is still investigational in the U.S., we were unable to market the device however, we were able to educate physicians about our technology, and by all counts, they were very impressed!

New Customers

TRT's service division, Shockwave Technical Service (STS), added 6 new customers this quarter including Sonocur, which operates more than 80 devices and is the nation's largest provider of shockwave treatment for plantar fasciitis and tennis elbow. STS also expanded its service to include the Medstone line of lithotripters and already added several new customers under this service line. Additionally, our first Dornier service contracts begin April 1st.

a world of thanks

Special thanks to Dr. Peter Sheehan and Dr. Christopher Attinger for inviting TRT, Dr. Wolfgang Schaden and former Senator Max Cleland to the prestigious Wound Healing: Industry and Science Meeting. Mr. Cleland was honored to provide a guest lecture and Dr. Schaden was privileged to present his initial wound data. TRT was most grateful for the opportunity to network with other key players in this industry such as Smith & Nephew, KCI and Organogenesis. The meeting was a monumental success!



in the spotlight



TRansiTions is taking a lighter approach to its interview segment, "In the Spotlight." This quarter we feature Michael Rozmajzl, TRT's General Counsel, an Initial Member and a Member of the Board of Managers.

Born: Akron, Ohio

Age: 35

Favorite book: "Healthcare Fraud and Abuse: A Practical Perspective" by Linda Baumann

Favorite foods: Braunschweiger and circus peanuts (the big, orange marshmallow kind)

Favorite past-time: Weight lifting and . . . well, he has 4 children and a set of twins on the way.

Favorite movie: "Cheaper by the Dozen"

Supporting roles: Wife of 10 years, Leanne; 4 daughters

Education: Bachelors degree in Accounting from Miami University; Law degree from Case Western Reserve University.

Previous Employment: CPA for PricewaterhouseCoopers in Vladivostok, Russia; practiced business, securities, and tax law at Kohrman, Jackson, & Krantz, PLL; had his own law and CPA practice in Akron, Ohio.

Anonymous Jabs/Quotes from Co-workers:

- "Upon realizing that we couldn't afford to hire an experienced attorney and CPA, we fortuitously found Michael. Not only is he cheap, but he is also an insomniac - a perfect match for a start-up venture!"
- "He is often the voice of reason and conservatism and is an invaluable member of our team."

Tissue Regeneration Technologies
110 Arnold Mill Park, Suite 400
Woodstock, Georgia 30188
Tel: (770) 966-1315
TDD: (877) 966-1315
Fax: (770) 592-8910
Email: jdodd@trtlc.com

